Utilizing Qualitative and Quantitative Methods to Understand a New Model of Type 1 and 2 Systemic Lupus Erythematosus (SLE)

Duke University

Status: Completed

Conditions: Systemic Lupus Erythematosus

Treatments: Behavioral: SLE@Duke

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT05426902

KL2TR002554 (U.S. NIH Grant/Contract)

Pro00102300

Details and patient eligibility

About

The purpose of this study is to pilot test SLE@Duke, a set of tools to implement the Type 1 & 2 SLE Model in a clinical setting, as well as to gain an in-depth understanding of providers experiences using the intervention during clinic visits with patients with systemic lupus erythematosus.

This record represents Aim 3 of this study.

Enrollment: 16 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All providers in Duke Rheumatology who practice outside of the Duke Lupus Clinic are eligible.
• Patients are eligible to participate if they have an established diagnosis of SLE and are followed in Duke Rheumatology.
• All patients with a SLE diagnosis will be included in the analysis. SLE diagnosis will be based on an ICD-10 code for SLE (M32.1*, M32.8, M32.9) in the EMR.

Exclusion criteria

• New patients will be excluded

Trial design

Primary purpose: Health Services Research

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

16 participants in 1 patient group

SLE@Duke

Experimental group

Description:

Clinic providers in Duke Rheumatology outside of the Duke Lupus Clinic are eligible to participate in the SLE@Duke intervention. Participants complete a baseline survey and training in the Type 1 \& 2 SLE Model. They are asked to perform the intervention for all eligible patients over 4 weeks. Patients complete a survey at the end of their clinic visit, and providers complete a survey at the end of the 4 week intervention period. All participating providers were invited to an in-depth interview at the end of the intervention period.

Treatment:

Behavioral: SLE@Duke